Stocks

Company news: Alembic Pharmaceuticals

| Updated on November 22, 2019 Published on November 22, 2019

Alembic Pharmaceuticals on Friday said it has received approvals from the United States Food and Drug Administration for its Deferasirox tablets in the strengths of 90 mg and 360 mg and Deferasirox tablets for oral suspension in the strengths of 125 mg, 250 mg, and 500 mg. The tablets are generic versions of Novartis Pharmaceuticals Corporation’s Jadenu tablets and Exjade tablets for oral suspension in the same strengths, it added. The company has also received tentative nod from the US health regulator for its Deferasirox tablets in the strength of 180 mg, Alembic Pharmaceuticals said. Shares of Alembic Pharma closed at ₹544.95, down 0.28 per cent.

Published on November 22, 2019
This article is closed for comments.
Please Email the Editor